Author Topic: (Abst.) Excessive risk of suicide may no longer be a reality for MS patients  (Read 133 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, March 17, 2017:

Quote
Mult Scler. 2017 Mar 1:

An excessive risk of suicide may no longer be a reality for multiple sclerosis patients

Kalson-Ray S1, Edan G2, Leray E3; SURVIMUS Study Group.

Author information

1
Ecole des Hautes Etudes en Santé Publique (EHESP), Département METIS, Rennes Cedex, France.
2
Service de Neurologie and CIC-P 1414, CHU de Rennes, Rennes Cedex, France.
3
Ecole des Hautes Etudes en Santé Publique (EHESP), Département METIS, Rennes Cedex, France; CIC-P 1414 CHU de Rennes, Rennes Cedex, France; and EA 7449 REPERES, Université de Rennes 1/EHESP, Rennes Cedex, France.


BACKGROUND:

Few recent studies have shown that there is no longer an increased risk of suicide in patients affected with multiple sclerosis (MS).

OBJECTIVES:

To describe suicide cases within a large French MS cohort and assess whether MS patients are at a higher risk of suicide compared with the general population.

METHODS:

Data derives from a study on long-term mortality of 27,603 prevalent cases from 15 MS specialist centres. Of 1,569 deceased MS patients (5.7%) on 1 January 2010, 47 were suicides.

RESULTS:

The mean time between MS clinical onset and death was 13.5 years (standard deviation (SD): 9.3 years; none within the first 3 years) and was significantly shorter than for MS patients who had died from other causes (mean = 21.4 (SD = 11.6), p < 0.0001). Age at death was also lower (46.3 vs 56.7). The standardized mortality rates were around 1 in several sensitivity analyses, reflecting no excess mortality in MS compared with general population.

CONCLUSION:

Our findings indicate that an excess suicide risk may no longer be true for MS patients and highlight the changing profile of cases, occurring later in the disease course. Further studies in population-based registries are needed to confirm and explain these potential changes (e.g. treatments' impact?).

https://www.ncbi.nlm.nih.gov/pubmed/28299961
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
158 Views
Last post October 25, 2016, 08:56:06 am
by agate
0 Replies
131 Views
Last post April 23, 2017, 03:47:31 pm
by agate
0 Replies
93 Views
Last post March 29, 2019, 08:07:16 am
by agate
0 Replies
41 Views
Last post November 23, 2019, 02:27:00 pm
by agate
0 Replies
16 Views
Last post March 12, 2023, 11:39:50 am
by agate